• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在 HLA-A2.1 转基因小鼠中,前体细胞频率和竞争决定了流感 A 感染和疫苗接种引起的 HLA-A2 限制性 CD8+ T 细胞反应。

Precursor frequency and competition dictate the HLA-A2-restricted CD8+ T cell responses to influenza A infection and vaccination in HLA-A2.1 transgenic mice.

机构信息

Department of Microbiology and Immunology, University of Melbourne, Parkville 3010, Victoria, Australia.

出版信息

J Immunol. 2011 Aug 15;187(4):1895-902. doi: 10.4049/jimmunol.1100664. Epub 2011 Jul 15.

DOI:10.4049/jimmunol.1100664
PMID:21765016
Abstract

The human HLA-A2-restricted CD8(+) T cell response to influenza A virus (IAV) is largely directed against the matrix protein-derived M1(58-66) epitope and represents an archetypal example of CD8(+) T cell immunodominance. In this study, we examined the CD8(+) T cell hierarchy to M1(58-66) and two subdominant IAV-specific epitopes: NS1(122-130) and PA(46-55) in HLA-A2(+) human subjects and HLA-A2.1 transgenic (HHD) mice. Using epitope-based lipopeptides, we show that the CD8(+) T cell hierarchy induced by IAV infection could also be induced by lipopeptide vaccination in a context outside of viral infection when the Ag load is equalized. In the HHD HLA-A2.1 mouse model, we show that the naive T cell precursor frequencies, and competition at the Ag presentation level, can predict the IAV-specific CD8(+) T cell hierarchy. Immunization of mice with subdominant epitopes alone was unable to overcome the dominance of the M1(58-66)-specific response in the face of IAV challenge; however, a multiepitope vaccination strategy was most effective at generating a broad and multispecific response to infection.

摘要

人类 HLA-A2 限制性 CD8(+) T 细胞对甲型流感病毒 (IAV) 的反应主要针对基质蛋白衍生的 M1(58-66) 表位,这是 CD8(+) T 细胞免疫优势的典型例子。在这项研究中,我们研究了 M1(58-66)和两个亚显性 IAV 特异性表位(NS1(122-130)和 PA(46-55))在 HLA-A2(+)人类受试者和 HLA-A2.1 转基因(HHD)小鼠中的 CD8(+) T 细胞优势等级。使用基于表位的脂肽,我们表明,当抗原负荷相等时,IAV 感染诱导的 CD8(+) T 细胞优势等级也可以通过脂肽疫苗接种在病毒感染之外的情况下诱导。在 HHD HLA-A2.1 小鼠模型中,我们表明,在面对 IAV 挑战时,幼稚 T 细胞前体频率和抗原呈递水平的竞争可以预测 IAV 特异性 CD8(+) T 细胞优势等级。单独用亚显性表位免疫小鼠无法克服 M1(58-66)-特异性反应的优势;然而,多表位疫苗接种策略在感染时最有效地产生广泛和多特异性的反应。

相似文献

1
Precursor frequency and competition dictate the HLA-A2-restricted CD8+ T cell responses to influenza A infection and vaccination in HLA-A2.1 transgenic mice.在 HLA-A2.1 转基因小鼠中,前体细胞频率和竞争决定了流感 A 感染和疫苗接种引起的 HLA-A2 限制性 CD8+ T 细胞反应。
J Immunol. 2011 Aug 15;187(4):1895-902. doi: 10.4049/jimmunol.1100664. Epub 2011 Jul 15.
2
The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus.设计和概念验证一种基于 CD8(+) T 细胞的疫苗,诱导针对甲型流感病毒的跨亚型保护。
Immunol Cell Biol. 2013 Jan;91(1):96-104. doi: 10.1038/icb.2012.54. Epub 2012 Nov 13.
3
Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2.可溶性蛋白通过与靶向 TLR2 的简单阳离子或阴离子脂质体静电结合,诱导强烈的 CD8+ T 细胞和抗体反应。
J Immunol. 2011 Aug 15;187(4):1692-701. doi: 10.4049/jimmunol.1100486. Epub 2011 Jul 8.
4
The immunodominant CD8 T cell response to the human cytomegalovirus tegument phosphoprotein pp65(495-503) epitope critically depends on CD4 T cell help in vaccinated HLA-A*0201 transgenic mice.人巨细胞病毒被膜磷蛋白 pp65(495-503)表位的免疫优势 CD8 T 细胞应答在接种 HLA-A*0201 转基因小鼠中严重依赖于 CD4 T 细胞的辅助作用。
J Immunol. 2011 Sep 1;187(5):2172-80. doi: 10.4049/jimmunol.1002512. Epub 2011 Aug 1.
5
Highly conserved pattern of recognition of influenza A wild-type and variant CD8+ CTL epitopes in HLA-A2+ humans and transgenic HLA-A2+/H2 class I-deficient mice.HLA-A2+人类和转基因HLA-A2+/H2 I类缺陷小鼠中甲型流感野生型和变异型CD8+CTL表位识别的高度保守模式。
Vaccine. 2005 Nov 1;23(45):5231-44. doi: 10.1016/j.vaccine.2005.07.032. Epub 2005 Jul 25.
6
Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.通过用痘苗病毒和天花病毒的单个CD8 + T细胞肽表位进行免疫接种,保护HLA - A2转基因小鼠免受致死性痘苗病毒攻击。
J Virol. 2004 Jul;78(13):7052-60. doi: 10.1128/JVI.78.13.7052-7060.2004.
7
Polyfunctional CD8(+) T cells are associated with the vaccination-induced control of a novel recombinant influenza virus expressing an HCV epitope.多功能 CD8(+) T 细胞与接种诱导控制表达 HCV 表位的新型重组流感病毒有关。
Antiviral Res. 2012 May;94(2):168-78. doi: 10.1016/j.antiviral.2012.03.009. Epub 2012 Apr 4.
8
Identification and immunogenicity of two new HLA-A*0201-restricted CD8+ T-cell epitopes on dengue NS1 protein.鉴定和免疫原性的两个新的 HLA-A*0201 限制性 CD8 + T 细胞表位登革热 NS1 蛋白。
Int Immunol. 2012 Apr;24(4):207-18. doi: 10.1093/intimm/dxr115. Epub 2012 Jan 31.
9
Redundancy of the influenza A virus-specific cytotoxic T lymphocyte response in HLA-B*2705 transgenic mice limits the impact of a mutation in the immunodominant NP(383-391) epitope on influenza pathogenesis.流感病毒特异性细胞毒性 T 淋巴细胞反应在 HLA-B*2705 转基因小鼠中的冗余限制了免疫优势 NP(383-391)表位突变对流感发病机制的影响。
Virus Res. 2011 Jan;155(1):123-30. doi: 10.1016/j.virusres.2010.09.008. Epub 2010 Sep 21.
10
Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.通过在小鼠中接种表达嵌合血凝素并结合核蛋白的MHC I类限制性表位的DNA疫苗,增强对H5N1流感病毒攻击的保护性免疫。
Antiviral Res. 2009 Mar;81(3):253-60. doi: 10.1016/j.antiviral.2008.12.009. Epub 2009 Jan 9.

引用本文的文献

1
Design and evaluation of a poly-epitope based vaccine for the induction of influenza A virus cross-reactive CD8 + T cell responses.基于多表位的甲型流感病毒交叉反应性CD8 + T细胞应答诱导疫苗的设计与评价
Sci Rep. 2025 Mar 27;15(1):10586. doi: 10.1038/s41598-025-95479-9.
2
Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy.治疗性癌症疫苗的进展、障碍及其在肿瘤免疫治疗中的前景
Mol Biotechnol. 2025 Apr;67(4):1336-1366. doi: 10.1007/s12033-024-01144-3. Epub 2024 Apr 16.
3
Therapeutic cancer vaccines: advancements, challenges, and prospects.
治疗性癌症疫苗:进展、挑战与展望。
Signal Transduct Target Ther. 2023 Dec 13;8(1):450. doi: 10.1038/s41392-023-01674-3.
4
Modified influenza M1 peptide vaccination induces non-relevant T-cells and may enhance pathology after challenge.改良型流感M1肽疫苗接种会诱导无关的T细胞,并且在受到攻击后可能会加重病理状况。
NPJ Vaccines. 2023 Aug 12;8(1):116. doi: 10.1038/s41541-023-00705-y.
5
Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination.不同 COVID-19 疫苗接种方案后产生的持久的刺突特异性 T 细胞反应,不会因加强针接种而进一步增强。
Sci Immunol. 2022 Dec 23;7(78):eadd3899. doi: 10.1126/sciimmunol.add3899. Epub 2022 Nov 1.
6
T cells in SARS-CoV-2 infection and vaccination.严重急性呼吸综合征冠状病毒2型感染与疫苗接种中的T细胞
Ther Adv Vaccines Immunother. 2022 Aug 24;10:25151355221115011. doi: 10.1177/25151355221115011. eCollection 2022.
7
Constant regulation for stable CD8 T-cell functional avidity and its possible implications for cancer immunotherapy.持续调节以稳定 CD8 T 细胞功能亲和力及其对癌症免疫治疗的可能影响。
Eur J Immunol. 2021 Jun;51(6):1348-1360. doi: 10.1002/eji.202049016. Epub 2021 Mar 30.
8
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition.SARS-CoV-2 衍生肽定义了异源和 COVID-19 诱导的 T 细胞识别。
Nat Immunol. 2021 Jan;22(1):74-85. doi: 10.1038/s41590-020-00808-x. Epub 2020 Sep 30.
9
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives.癌症 DNA 疫苗:当前的临床前和临床进展及未来展望。
J Exp Clin Cancer Res. 2019 Apr 5;38(1):146. doi: 10.1186/s13046-019-1154-7.
10
T Cell Immunity To Enterovirus 71 Infection In Humans And Implications For Vaccine Development.人类对肠道病毒 71 型感染的 T 细胞免疫反应及其对疫苗开发的意义。
Int J Med Sci. 2018 Jul 25;15(11):1143-1152. doi: 10.7150/ijms.26450. eCollection 2018.